SEATTLE CHILDREN’S signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors. The aim of the collaboration is to fast-track clinical implementation with the goal of opening phase I clinical trials within the next two years....
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
